glp-1 agonist drug interactions Frontiers A Comprehensive Review on the

Unlike many current weight-loss drugs that focus mainly on GLP-1 activity, retatrutide targets three hormone pathways: GIP, GLP-1, and glucagon

Epidemiological data from the International Diabetes Federation (IDF) indicate that the global burden of diabetes affected approximately 463 million adults in 2019, with projections estimating a dramatic increase to 700 million cases by 2045 2

doi: 10.1016/S2213-8587(21)00246-1 [DOI] [PubMed] [Google Scholar] 21

The use of prazosin, an 1-adrenergic receptor blocker, showed that the ability of GLP-1RAs to reduce TNF- in plasma was disrupted, signifying the vital role of 1-adrenergic receptors in the anti-inflammatory action of GLP-1RAs